Efficacy and safety data of AK002, an anti-siglec-8 monoclonal antibody, in patients with multiple forms of uncontrolled chronic urticaria (CU): Results from an open-label phase 2a study

Authors
Category Primary study
ConferenceAllergy: European Journal of Allergy and Clinical Immunology
Year 2019
This article has no abstract
Epistemonikos ID: 12785367942d0976b6c275229135b7cccebbc2d5
First added on: Apr 29, 2026